Basic Information
RNALocate ID: | RLID:11003623 |
RNA Symbol: | hsa-miR-29b-2-5p |
Localization: | Microvesicle |
RNA Information
RNA Name: | hsa-miR-29b-2-star |
RNA ID: | miRBase:MIMAT0004515 |
RNA Category: | miRNA |
Species: | Homo sapiens |
Localization Information
PubMed ID: | 23539611 |
Tissue/Cell Line: | Seminal plasma |
Method: | Microarray |
Description: | In order to assess the reversibility of post-vasectomy miRNA sequelae, we investigated whether SMV miRNAs altered by vasectomy could be retrieved in SMVs from normospermic vasovasostomized donors. miRNA microarray profiling performed on SMVs from normal, vasectomized and vasovasostomized donors identified 313 miRNAs whose intensity was above the threshold of detection. Among these miRNAs, 293 were detected in samples from normal donors, 275 in vasectomized donors and 298 in vasovasostomized donors (Fig. 3, Supplementary data, Table SIV). Data are collected from Table S4. |
Other Subcellular Localization
RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
RLID:01002585 | Mitochondrion | Skeletal muscle myoblasts | 21637849 |
RLID:11003622 | Exosome | Plasma | 23663360 |
RLID-D:11000592 | Microvesicle | Fibroblasts|Mesenchymal stem cells | |
RLID-D:11001471 | Exosome | Breast milk|Cell lines|Epididymal epithelial cells|Osteoblast|Plasma|Primary glioblastoma neurosphere cells|Primary keratinocyte|Saliva|Serum|Urine |
ncRNA Disease Information
Resource | RNA Symbol | Disease | Link |
MNDR | hsa-miR-29b-2-5p | Oral squamous cell carcinoma | MNDR-E-MI-35168 |
MNDR | hsa-miR-29b-2-5p | High-grade serous ovarian carcinoma | MNDR-E-MI-35169 |
MNDR | hsa-miR-29b-2-5p | Ovarian clear cell carcinoma | MNDR-E-MI-35170 |
MNDR | hsa-miR-29b-2-5p | Uterine corpus endometrial carcinoma | MNDR-E-MI-35171 |
MNDR | hsa-miR-29b-2-5p | Lymphoma | MNDR-E-MI-35172 |
MNDR | hsa-miR-29b-2-5p | Estrogen-receptor positive breast cancer | MNDR-E-MI-35173 |
MNDR | hsa-miR-29b-2-5p | Estrogen-receptor negative breast cancer | MNDR-E-MI-35174 |
MNDR | hsa-miR-29b-2-5p | Progesterone-receptor positive breast cancer | MNDR-E-MI-35175 |
MNDR | hsa-miR-29b-2-5p | Progesterone-receptor negative breast cancer | MNDR-E-MI-35176 |
MNDR | hsa-miR-29b-2-5p | Her2-receptor positive breast cancer | MNDR-E-MI-35177 |
MNDR | hsa-miR-29b-2-5p | Precursor cell lymphoblastic leukemia-lymphoma | MNDR-E-MI-35178 |
MNDR | hsa-miR-29b-2-5p | B cell acute lymphoblastic leukemia | MNDR-E-MI-35179 |
MNDR | hsa-miR-29b-2-5p | Prostate cancer | MNDR-E-MI-35180 |
MNDR | hsa-miR-29b-2-5p | Chronic lymphocytic leukemia | MNDR-E-MI-35181 |
MNDR | hsa-miR-29b-2-5p | Alzheimer disease | MNDR-E-MI-35182 |
MNDR | hsa-miR-29b-2-5p | Intracranial aneurysm | MNDR-E-MI-35183 |
MNDR | hsa-miR-29b-2-5p | Esophageal carcinoma | MNDR-E-MI-35184 |
MNDR | hsa-miR-29b-2-5p | Leukemia | MNDR-E-MI-35185 |
MNDR | hsa-miR-29b-2-5p | Lung cancer | MNDR-E-MI-35186 |
MNDR | hsa-miR-29b-2-5p | Parkinson disease | MNDR-E-MI-35187 |
MNDR | hsa-miR-29b-2-5p | Breast cancer | MNDR-E-MI-35188 |
MNDR | hsa-miR-29b-2-5p | Thyroid cancer | MNDR-E-MI-35189 |
MNDR | hsa-miR-29b-2-5p | Pancreatic cancer | MNDR-E-MI-35190 |
MNDR | hsa-miR-29b-2-5p | Melanoma | MNDR-E-MI-35191 |
MNDR | hsa-miR-29b-2-5p | Rectum adenocarcinoma | MNDR-E-MI-35192 |
MNDR | hsa-miR-29b-2-5p | Nephroblastoma | MNDR-E-MI-35193 |
MNDR | hsa-miR-29b-2-5p | Colon cancer | MNDR-E-MI-35194 |
MNDR | hsa-miR-29b-2-5p | Colon adenocarcinoma | MNDR-E-MI-35195 |
MNDR | hsa-miR-29b-2-5p | Multiple sclerosis relapsing-remitting | MNDR-E-MI-35196 |
MNDR | hsa-miR-29b-2-5p | Prostate adenocarcinoma | MNDR-E-MI-35197 |
MNDR | hsa-miR-29b-2-5p | Glioblastoma | MNDR-E-MI-35198 |
MNDR | hsa-miR-29b-2-5p | Rhabdomyosarcoma | MNDR-E-MI-35199 |
MNDR | hsa-miR-29b-2-5p | Osteosarcoma | MNDR-E-MI-35200 |
MNDR | hsa-miR-29b-2-5p | Infarction middle cerebral artery | MNDR-E-MI-35201 |
MNDR | hsa-miR-29b-2-5p | Gastric adenocarcinoma | MNDR-E-MI-35202 |
MNDR | hsa-miR-29b-2-5p | Cervical squamous cell carcinoma | MNDR-E-MI-35203 |
MNDR | hsa-miR-29b-2-5p | Lung squamous cell carcinoma | MNDR-E-MI-35204 |
MNDR | hsa-miR-29b-2-5p | Lung adenocarcinoma | MNDR-E-MI-35205 |
MNDR | hsa-miR-29b-2-5p | Ovarian carcinoma | MNDR-E-MI-35206 |
MNDR | hsa-miR-29b-2-5p | Bladder urothelial carcinoma | MNDR-E-MI-35207 |
MNDR | hsa-miR-29b-2-5p | Pancreatic adenocarcinoma | MNDR-E-MI-35208 |
MNDR | hsa-miR-29b-2-5p | Carcinoma renal cell | MNDR-E-MI-35209 |
MNDR | hsa-miR-29b-2-5p | Kidney renal papillary cell carcinoma | MNDR-E-MI-35210 |
MNDR | hsa-miR-29b-2-5p | Renal clear cell carcinoma | MNDR-E-MI-35211 |
MNDR | hsa-miR-29b-2-5p | Cholangiocarcinoma | MNDR-E-MI-35212 |
MNDR | hsa-miR-29b-2-5p | Head and neck squamous cell carcinoma | MNDR-E-MI-35213 |
MNDR | hsa-miR-29b-2-5p | T acute lymphoblastic leukemia | MNDR-E-MI-35214 |
MNDR | hsa-miR-29b-2-5p | Acute t cell leukemia | MNDR-E-MI-35215 |
MNDR | hsa-miR-29b-2-5p | Adenoma | MNDR-E-MI-35216 |
MNDR | hsa-miR-29b-2-5p | Hepatocellular carcinoma | MNDR-E-MI-35217 |
MNDR | hsa-miR-29b-2-5p | Acute myelocytic leukemia | MNDR-E-MI-35218 |
MNDR | hsa-miR-29b-2-5p | Colorectal cancer | MNDR-E-MI-35219 |
MNDR | hsa-miR-29b-2-5p | Nasopharynx carcinoma | MNDR-E-MI-35220 |
MNDR | hsa-miR-29b-2-5p | Nasopharyngeal cancer | MNDR-E-MI-35221 |
MNDR | hsa-miR-29b-2-5p | Breast cancer her3+ negative | MNDR-E-MI-35222 |
MNDR | hsa-miR-29b-2-5p | Solid-pseudopapillary neoplasm of pancreas | MNDR-E-MI-35223 |
RNA Interaction Information
Resource | RNA Symbol | Species | Link | RNALocate ID |
RNAInter | CASP3 | Homo sapiens | RR00278967 |
TOP